Revolutionizing Care: NeuroQure’s Groundbreaking Path to Treating Genetic Intellectual Disabilities
06 nov. 2023 12h00 HE
|
NeuroQure
IRVINE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- NeuroQure has embarked on a transformative journey aimed at revolutionizing the treatment landscape for Fragile X Syndrome and Autism Spectrum...
Neuronascent Announces the Expansion of its Board of Directors
12 avr. 2023 06h00 HE
|
Neuronascent, Inc.
ROCKVILLE, Md., April 12, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., a clinical-stage, neuron generating, biopharmaceutical company, is pleased to announce the addition of industry leader Emer...
Lenire Biosciences Completes License Agreement with University College London for VSN16R, A Novel Clinical Candidate Treatment for Fragile X Syndrome
16 juin 2022 08h59 HE
|
Lenire Biosciences
SAN DIEGO, June 16, 2022 (GLOBE NEWSWIRE) -- Lenire Biosciences Inc., a biopharmaceutical company developing novel treatments for Fragile X Syndrome (FXS) and related disorders, today announced that...
Neuronascent Receives FDA Orphan Drug Designation for NNI-351 Treatment of Fragile X Syndrome
01 juin 2022 06h00 HE
|
Neuronascent, Inc.
ROCKVILLE, Md., June 01, 2022 (GLOBE NEWSWIRE) -- Neuronascent Inc, today announced that the U.S. Food and Drug Administration (FDA) granted “Orphan Drug Designation” for the company’s NNI-351...
Neuronascent Receives FDA Rare Pediatric Drug Designation for NNI-351 Treatment for Fragile X Syndrome
24 mai 2022 06h00 HE
|
Neuronascent, Inc.
ROCKVILLE, Md., May 24, 2022 (GLOBE NEWSWIRE) -- Neuronascent Inc., a clinical-stage biopharmaceutical company discovering and developing neuron-generating therapies for rare developmental...
Fragile X Syndrome Clinical Trials Pipeline Offers Promising Novel Treatment Options | DelveInsight
30 mars 2022 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, March 30, 2022 (GLOBE NEWSWIRE) -- Fragile X Syndrome Clinical Trials Pipeline Offers Promising Novel Treatment Options | DelveInsight Fragile X Syndrome is a life-long disorder...